**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 81168

**Manuscript Type:** LETTER TO THE EDITOR

**Celiac disease screening in patients with cryptogenic cirrhosis**

Narciso-Schiavon JL *et al*. Celiac disease and cryptogenic cirrhosis

Janaina Luz Narciso-Schiavon, Leonardo Lucca Schiavon

**Janaina Luz Narciso-Schiavon, Leonardo Lucca Schiavon,** Gastroenterology Division, Internal Medicine Department, Federal University of Santa Catarina, Florianopolis 88040-900, SC, Brazil

**Author contributions:** Narciso-Schiavon JL and Schiavon LL designed the research; Narciso-Schiavon JL wrote the paper; and Schiavon LL reviewed the manuscript.

**Corresponding author: Janaina Luz Narciso-Schiavon, MD, PhD, Associate Professor,** Gastroenterology Division, Internal Medicine Department, Federal University of Santa Catarina, R Maria Flora Pasewang S/N, Florianopolis 88040-900, SC, Brazil. janaina.narciso@uol.com.br

**Received:** October 27, 2022

**Revised:** November 26, 2022

**Accepted:** December 21, 2022

**Published online:**

**Abstract**

We write a letter to the editor commenting the article “Who to screen and how to screen for celiac disease”. We discuss the present literature on cirrhosis and celiac disease (CD) and recommend screening and treating CD in individuals with cryptogenic cirrhosis.

**Key Words:** Celiac disease; Liver cirrhosis; Liver failure; Aspartate aminotransferase; Alanine aminotransferase

Narciso-Schiavon JL, Schiavon LL. Celiac disease screening in patients with cryptogenic cirrhosis. *World J Gastroenterol* 2022; In press

**Core Tip:** We discuss reasons for recommendation of celiac disease screening in patients with cryptogenic cirrhosis.

**TO THE EDITOR**

We read with interest the article by Singh *et al*[1]. Liver cirrhosis is a disease with potential morbidity, which can progress to decompensation, hepatocellular carcinoma and death. A high proportion (9.15%) of patients with cryptogenic hypertransaminasemia is affected by asymptomatic celiac disease (CD)[2]. It has been proposed that the hepatic manifestation of CD is a nonspecific chronic hepatitis[3], called by some authors celiac hepatitis[4]. A higher prevalence of CD has been demonstrated in individuals with autoimmune hepatitis[5], and anti-actin antibodies may be present in both diseases, as they are reliable for the diagnosis of type-1 autoimmune hepatitis[6] and can also be associated with severe intestinal mucosa damage in CD patients[7]. This could support an immunological link between CD and liver injury. Despite these findings, it is not known for sure whether liver disease associated with celiac has the potential to progress to liver cirrhosis, although CD is twice as common in individuals with cirrhosis of the liver as in the general population[8,9]. In this sense, studies suggest that CD can be a cause of cryptogenic cirrhosis[10,11]. Most importantly, it has been reported that a gluten-free diet (GFD) treatment can reverse the decompensation of cirrhosis and remove the patient from liver transplantation waiting list[12-14]. Joshi *et al*[9] evaluated 84 patients with chronic liver disease, and 13% were diagnosed with CD. An improvement in liver function tests and Child-Pugh score was observed after GFD treatment. Demir *et al*[10] reported five cases of children with cryptogenic cirrhosis and CD. Treatment with GFD leaded to clinical and biochemical improvement, followed by a decrease in liver and spleen size. The most important sample was reported by Wakim-Fleming *et al*[8]. They have evaluated 204 patients with biopsy proven cirrhosis of different causes, and 2.5% were diagnosed with CD. After a GFD, patients with CD showed a return to normal levels of their celiac antibodies, small bowel biopsy and liver enzymes, and none received a liver transplant[8]. The European Society for the Study of Celiac Disease states that patients with unexplained elevation of liver enzymes should be assessed for CD and recognizes that CD can be associated with severe liver disease and even liver failure[15].

For the aforementioned reasons, and because liver cirrhosis has a high potential for morbidity and mortality, we recommend screening and treating CD in individuals with cryptogenic cirrhosis[16]. And one should consider screening for celiac antibodies in patients with decompensated cirrhosis on the liver transplantation waiting list, whatever are the mechanisms involved in the deterioration of liver function.

**REFERENCES**

1 **Singh P**, Singh AD, Ahuja V, Makharia GK. Who to screen and how to screen for celiac disease. *World J Gastroenterol* 2022; **28**: 4493-4507 [PMID: 36157923 DOI: 10.3748/wjg.v28.i32.4493]

2 **Volta U**, Granito A, De Franceschi L, Petrolini N, Bianchi FB. Anti tissue transglutaminase antibodies as predictors of silent coeliac disease in patients with hypertransaminasaemia of unknown origin. *Dig Liver Dis* 2001; **33**: 420-425 [PMID: 11529654 DOI: 10.1016/s1590-8658(01)80014-1]

3 **Nehra V**, Angulo P, Buchman AL, Lindor KD. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. *Dig Dis Sci* 2001; **46**: 2347-2352 [PMID: 11713934 DOI: 10.1023/a:1012338828418]

4 **Rubio-Tapia A**, Murray JA. The Liver and Celiac Disease. *Clin Liver Dis* 2019; **23**: 167-176 [PMID: 30947869 DOI: 10.1016/j.cld.2018.12.001]

5 **Haggård L**, Glimberg I, Lebwohl B, Sharma R, Verna EC, Green PHR, Ludvigsson JF. High prevalence of celiac disease in autoimmune hepatitis: Systematic review and meta-analysis. *Liver Int* 2021; **41**: 2693-2702 [PMID: 34219350 DOI: 10.1111/liv.15000]

6 **Granito A**, Muratori L, Muratori P, Pappas G, Guidi M, Cassani F, Volta U, Ferri A, Lenzi M, Bianchi FB. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. *J Clin Pathol* 2006; **59**: 280-284 [PMID: 16505279 DOI: 10.1136/jcp.2005.027367]

7 **Carroccio A**, Brusca I, Iacono G, Alessio MG, Sonzogni A, Di Prima L, Barrale M, Ottomano C, Ambrosiano G, Teresi S, D'Angelo A, Pirrone G, Cefalù B, Scalici C, La Chiusa SM. IgA anti-actin antibodies ELISA in coeliac disease: a multicentre study. *Dig Liver Dis* 2007; **39**: 818-823 [PMID: 17652043 DOI: 10.1016/j.dld.2007.06.004]

8 **Wakim-Fleming J**, Pagadala MR, McCullough AJ, Lopez R, Bennett AE, Barnes DS, Carey WD. Prevalence of celiac disease in cirrhosis and outcome of cirrhosis on a gluten free diet: a prospective study. *J Hepatol* 2014; **61**: 558-563 [PMID: 24842303 DOI: 10.1016/j.jhep.2014.05.020]

9 **Joshi A**, Falodia S, Kumar N, Gupta P, Khatri PC. Prevalence of celiac disease among pediatric patients with cryptogenic cirrhosis and effect of gluten-free-diet. *Indian J Gastroenterol* 2018; **37**: 243-247 [PMID: 29948993 DOI: 10.1007/s12664-018-0857-6]

10 **Demir H**, Yüce A, Caglar M, Kale G, Kocak N, Ozen H, Gürakan F, Saltik-Temizel IN. Cirrhosis in children with celiac disease. *J Clin Gastroenterol* 2005; **39**: 630-633 [PMID: 16000933 DOI: 10.1097/01.mcg.0000170734.49725.53]

11 **Duman AE**, Oğütmen Koç D, Korkmaz U, Tohumcu A, Celebi A, Sentürk O, Hülagü S, Erçin C. Cirrhosis and intestinal B-cell lymphoma: two entities that are rarely associated with celiac disease. *Turk J Gastroenterol* 2013; **24**: 192-194 [PMID: 23934474 DOI: 10.4318/tjg.2013.0478]

12 **Roumeliotis N**, Hosking M, Guttman O. Celiac disease and cardiomyopathy in an adolescent with occult cirrhosis. *Paediatr Child Health* 2012; **17**: 437-439 [PMID: 24082804 DOI: 10.1093/pch/17.8.437]

13 **Ratziu V**, Nourani M, Poynard T. Discussion on celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. *Gastroenterology* 2002; **123**: 2158-9; author reply 2159-60 [PMID: 12454882 DOI: 10.1053/gast.2002.37302]

14 **Al-Hussaini A**, Basheer A, Czaja AJ. Liver failure unmasks celiac disease in a child. *Ann Hepatol* 2013; **12**: 501-505 [PMID: 23619270]

15 **Al-Toma A**, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, Mulder CJ, Lundin KEA. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. *United European Gastroenterol J* 2019; **7**: 583-613 [PMID: 31210940 DOI: 10.1177/2050640619844125]

16 **Narciso-Schiavon JL**, Schiavon LL. To screen or not to screen? Celiac antibodies in liver diseases. *World J Gastroenterol* 2017; **23**: 776-791 [PMID: 28223722 DOI: 10.3748/wjg.v23.i5.776]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** Sociedade Brasileira de Hepatologia; Associação Latinoamericana para Estudo do Fígado; and Associação Catarinense para Estudo do Fígado.

**Peer-review started:** October 27, 2022

**First decision:** November 26, 2022

**Article in press:**

**Specialty type:** Gastroenterology and Hepatology

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Beenet L, United States; Taavela J, Finland **S-Editor:** Gong ZM **L-Editor:** A **P-Editor:** Gong ZM